Report initial interim data from the registration-directed anti-PD1 failed cutaneous melanoma cohort
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 30 Mar 2022
- Due
- 31 Dec 2022
- Delivered
- December 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“registration-directed 125 patient cohort of anti-PD1 failed cutaneous melanoma where an initial interim readout is expected in late 2022”
What we found
Evidence strength A What the grades mean
The company reported an interim data update from the registration-directed anti-PD1 failed melanoma cohort in December 2022, meeting the late 2022 deadline.
-
A Replimune Group, Inc. 8-K filed 2023-02-09
“We ended 2022 with a data update from our registration directed IGNYTE cohort of RP1 in anti-PD1 failed melanoma that demonstrated impressive and clinically meaningful activity” ✓ confirmed on the page
Market reaction: the shares moved -11.9% against the S&P 500 over the three sessions around the disclosure (8 Feb 2023 to 13 Feb 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- interim readout for anti-PD1 failed cutaneous melanoma cohort
- Target
- 125 patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-REPL-002668 · Corrections policy